|
1
|
Mazur MT and Clark HB: Gastric stromal
tumors: Reappraisal of histogenesis. Am J Surg Pathol. 7:507–519.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors. Gastroenterol Clin North Am. 42:399–415. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duensing A, Heinrich MC, Fletcher CD and
Fletcher JA: Biology of gastrointestinal stromal tumors: KIT
mutations and beyond. Cancer Invest. 22:106–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sako H, Fukuda K, Saikawa Y, Nakamura R,
Takahashi T, Wada N, Kawakubo H, Takeuchi H, Ohmori T and Kitagawa
Y: Antitumor effect of the tyrosine kinase inhibitor nilotinib on
gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST
cells. PLoS One. 9:e1076132014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Demetri GD, Reichardt P, Kang YK, Blay JY,
Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M,
Joensuu H, et al: Efficacy and safety of regorafenib for advanced
gastrointestinal stromal tumours after failure of imatinib and
sunitinib (GRID): An international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rossi F, Ehlers I, Agosti V, Socci ND,
Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR and Besmer P:
Oncogenic Kit signaling and therapeutic intervention in a mouse
model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA.
103:pp. 12843–12848. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patel S: Exploring novel therapeutic
targets in GIST: Focus on the PI3K/Akt/mTOR pathway. Curr Oncol
Rep. 15:386–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y, Yang J, Liao W, Liu X, Zhang H,
Wang S, Wang D, Feng J, Yu L and Zhu WG: Cytosolic FoxO1 is
essential for the induction of autophagy and tumour suppressor
activity. Nat Cell Biol. 12:665–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prasad SB, Yadav SS, Das M, Govardhan HB,
Pandey LK, Singh S, Pradhan S and Narayan G: Down regulation of
FOXO1 promotes cell proliferation in cervical cancer. J Cancer.
5:655–662. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsumoto M, Pocai A, Rossetti L, Depinho
RA and Accili D: Impaired regulation of hepatic glucose production
in mice lacking the forkhead transcription factor Foxo1 in liver.
Cell Metab. 6:208–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ai J, Duan J, Lv X, Chen M, Yang Q, Sun H,
Li Q, Xiao Y, Wang Y, Zhang Z, et al: Overexpression of FoxO1
causes proliferation of cultured pancreatic beta cells exposed to
low nutrition. Biochemistry. 49:218–225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taguchi T, Sonobe H, Toyonaga S, Yamasaki
I, Shuin T, Takano A, Araki K, Akimaru K and Yuri K: Conventional
and molecular cytogenetic characterization of a new human cell
line, GIST-T1, established from gastrointestinal stromal tumor. Lab
Invest. 82:663–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu KH, Tsai HW, Lin PW, Hsu YS, Lu PJ and
Shan YS: Anti-apoptotic effects of osteopontin through the
up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J
Surg Oncol. 12:1892014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado
M, Sánchez-León M, Trigo-Sánchez I, Padillo JP, Amérigo J and
González-Cámpora R: Differential activation of MAPK and
PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal
stromal tumors. Anticancer Res. 31:3019–3025. 2011.PubMed/NCBI
|
|
18
|
Heinrich MC, Corless CL, Blanke CD,
Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M,
Fletcher CD, Sandau K, et al: Molecular correlates of imatinib
resistance in gastrointestinal stromal tumors. J Clin Oncol.
24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sykes SM, Lane SW, Bullinger L,
Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H,
Brumme KM, et al: AKT/FOXO signaling enforces reversible
differentiation blockade in myeloid leukemias. Cell. 146:697–708.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Asada S, Daitoku H, Matsuzaki H, Saito T,
Sudo T, Mukai H, Iwashita S, Kako K, Kishi T, Kasuya Y and Fukamizu
A: Mitogen-activated protein kinases, Erk and p38, phosphorylate
and regulate Foxo1. Cell Signal. 19:519–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiang L, Banks AS and Accili D: Uncoupling
of acetylation from phosphorylation regulates FoxO1 function
independent of its subcellular localization. J Biol Chem.
285:27396–27401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moriishi T, Kawai Y, Komori H, Rokutanda
S, Eguchi Y, Tsujimoto Y, Asahina I and Komori T: Bcl2 deficiency
activates FoxO through Akt inactivation and accelerates osteoblast
differentiation. PLoS One. 9:e866292014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teijido O and Dejean L: Upregulation of
Bcl2 inhibits apoptosis-driven BAX insertion but favors BAX
relocalization in mitochondria. FEBS Lett. 584:3305–3310. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim SJ, Winter K, Nian C, Tsuneoka M, Koda
Y and McIntosh CH: Glucose-dependent insulinotropic polypeptide
(GIP) stimulation of pancreatic beta-cell survival is dependent
upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)
signaling, inactivation of the forkhead transcription factor Foxo1,
and down-regulation of bax expression. J Biol Chem.
280:22297–22307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muranen T, Selfors LM, Worster DT,
Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS:
Inhibition of PI3K/mTOR leads to adaptive resistance in
matrix-attached cancer cells. Cancer Cell. 21:227–239. 2012.
View Article : Google Scholar : PubMed/NCBI
|
